Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.67 |
| ▸ | RRM1 | P23921 | 1/20 | 0.66 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.62 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.62 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.57 |
| ▸ | CASP2 | P42575 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795617 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL3791159 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL31283221 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL29238181 | 1.00 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL31284074 | 0.91 | SLC6A5 (0.58) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL16328504 | 0.90 | RRM1 (0.62) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL31282849 | 0.87 | CNR1 (0.58) | — | |
| SCHEMBL24696810 | 0.86 | CASP2 (0.55) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL7769954 | 0.86 | DPP7 (0.67) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL733986 | 0.86 | CASP2 (0.55) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812152-B2 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-10-12 | — | — | US | disclosed |
| US-20070142324-A1 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142324-A1 | Amphiphilic cyclodextrin derivatives, method for preparation thereof and uses thereof | CLTA, PDIA5, ABCC5 | DPP7 3512/4885RRM1 3141/4885GNAI3 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.